Q-omics provides the consensus-scored DENND2C profile across patient tissues and cancer cell-line models. DENND2C expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, DENND2C is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, DENND2C RNA expression shows 19,167 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, KICH, and KIRP as cancer lineages where DENND2C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND2C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND2C survival associations across molecular data types. DENND2C RNA expression shows survival associations in the most cancer types (22), followed by mutation status (11) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND2C RNA expression–survival associations across cancer types. High DENND2C expression shows unfavorable associations in UCEC, STAD and KIRP, but favorable associations in KIRC, UVM and LUSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for DENND2C RNA expression.
This table summarizes DENND2C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DENND2C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND2C shows lower tumor expression in KICH, THCA, LUAD and BRCA and higher tumor expression in LUSC and LIHC. The KICH box plot shows higher DENND2C RNA expression in normal versus tumor tissue (log2 FC = −0.837, t-test p < 0.001).
This table shows molecular features associated with DENND2C in patient tissues and cancer cell lines. In patient samples, DENND2C shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND2C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
